Corvus Pharmaceuticals Inc. hopes to catch the next wave of the immuno-oncology revolution by developing drugs that can treat patients who are resistant/refractory to PD-1/L1 inhibitors, by blocking the effects of the signaling molecule adenosine.
It's impossible to overestimate the impact that checkpoint inhibitors have had in cancer treatment. In some tumor types, however, response is limited and PD-1/L1 inhibitors may only work in 20%...
Corvus Pharmaceuticals
Location: Burlingame, Calif.
R&D Focus: Immuno-oncology
Disease Areas: Cancer
Founding Date: 2014
Founders: Richard Miller, Joseph Buggy, Peter Thompson
...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
